Radiopharm Theranostics Files 6-K for December 2024
Ticker: RDPTF · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, routine-report
TL;DR
Radiopharm Theranostics (RPT) filed its monthly 6-K for Dec 2024, standard foreign issuer update.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on December 30, 2024, reporting information for the month of December 2024. The company is a foreign private issuer based in Australia, incorporated in C3, with its principal executive office located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053. Radiopharm Theranostics Limited operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides routine updates for foreign private issuers, informing the SEC and investors about the company's activities and status during the reporting period.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 0001213900-24-113231 (filing_id) — Accession Number
- 20241230 (date) — Filing Date
- 001-41621 (company_id) — SEC File Number
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (address) — Principal Executive Office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the company makes or is required to make public in its home country.
What is the filing date of this specific 6-K?
The filing date of this 6-K is December 30, 2024.
What is the SEC file number for Radiopharm Theranostics Limited?
The SEC file number for Radiopharm Theranostics Limited is 001-41621.
Where is Radiopharm Theranostics Limited's principal executive office located?
Radiopharm Theranostics Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Radiopharm Theranostics Limited file annual reports under Form 20-F or 40-F?
Radiopharm Theranostics Limited indicates it files annual reports under cover of Form 20-F.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 19.5 · Accepted 2024-12-30 06:31:23
Filing Documents
- ea0226256-6k_radio.htm (6-K) — 12KB
- ea022625601ex99-1_radio.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001213900-24-113231.txt ( ) — 39KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on December 30, 2024 titled: - “Strategic Co-Development Partnership with Lantheus for Aus” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 30 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3